BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37140539)

  • 21. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review.
    Davies R; Gaynor D; Hyrich KL; Pain CE
    Semin Arthritis Rheum; 2017 Apr; 46(5):584-593. PubMed ID: 27914689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis.
    Giannini EH; Ilowite NT; Lovell DJ; Wallace CA; Rabinovich CE; Reiff A; Higgins G; Gottlieb B; Singer NG; Chon Y; Lin SL; Baumgartner SW;
    Arthritis Rheum; 2009 Sep; 60(9):2794-804. PubMed ID: 19714630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcome of children with oligoarticular juvenile idiopathic arthritis compared to polyarthritis on methotrexate- data of the German BIKER registry.
    Raab A; Kallinich T; Huscher D; Foeldvari I; Weller-Heinemann F; Dressler F; Kuemmerle-Deschner JB; Klein A; Horneff G
    Pediatr Rheumatol Online J; 2021 Mar; 19(1):41. PubMed ID: 33752685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial.
    Brunner HI; Foeldvari I; Alexeeva E; Ayaz NA; Calvo Penades I; Kasapcopur O; Chasnyk VG; Hufnagel M; Żuber Z; Schulert G; Ozen S; Rakhimyanova A; Ramanan A; Scott C; Sozeri B; Zholobova E; Martin R; Zhu X; Whelan S; Pricop L; Martini A; Lovell D; Ruperto N;
    Ann Rheum Dis; 2023 Jan; 82(1):154-160. PubMed ID: 35961761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study.
    Lahdenne P; Vähäsalo P; Honkanen V
    Ann Rheum Dis; 2003 Mar; 62(3):245-7. PubMed ID: 12594111
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study.
    Hissink Muller PC; Brinkman DM; Schonenberg D; Koopman-Keemink Y; Brederije IC; Bekkering WP; Kuijpers TW; van Rossum MA; van Suijlekom-Smit LW; van den Berg JM; Allaart CF; Ten Cate R
    Pediatr Rheumatol Online J; 2017 Feb; 15(1):11. PubMed ID: 28166785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Etanercept concentration and immunogenicity do not influence the response to Etanercept in patients with juvenile idiopathic arthritis.
    Bader-Meunier B; Krzysiek R; Lemelle I; Pajot C; Carbasse A; Poignant S; Melki I; Quartier P; Choupeaux L; Henry E; Treluyer JM; Belot A; Hacein-Bey-Abina S; Urien S
    Semin Arthritis Rheum; 2019 Jun; 48(6):1014-1018. PubMed ID: 30396593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan.
    Mori M; Takei S; Imagawa T; Imanaka H; Nerome Y; Higuchi R; Kawano Y; Yokota S; Sugiyama N; Yuasa H; Fletcher T; Wajdula JS
    Mod Rheumatol; 2012 Sep; 22(5):720-6. PubMed ID: 22212889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis.
    Windschall D; Horneff G
    Clin Rheumatol; 2016 Dec; 35(12):2925-2931. PubMed ID: 27709443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
    Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
    JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label Study.
    Brunner HI; Tzaribachev N; Vega-Cornejo G; Louw I; Berman A; Calvo Penadés I; Antón J; Ávila-Zapata F; Cuttica R; Horneff G; Foeldvari I; Keltsev V; Kingsbury DJ; Viola DO; Joos R; Lauwerys B; Paz Gastañaga ME; Rama ME; Wouters C; Bohnsack J; Breedt J; Fischbach M; Lutz T; Minden K; Miraval T; Ally MMTM; Rubio-Pérez N; Solau Gervais E; van Zyl R; Li X; Nys M; Wong R; Banerjee S; Lovell DJ; Martini A; Ruperto N;
    Arthritis Rheumatol; 2018 Jul; 70(7):1144-1154. PubMed ID: 29481737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early combination therapy with etanercept and methotrexate in JIA patients shortens the time to reach an inactive disease state and remission: results of a double-blind placebo-controlled trial.
    Alexeeva E; Horneff G; Dvoryakovskaya T; Denisova R; Nikishina I; Zholobova E; Malievskiy V; Santalova G; Stadler E; Balykova L; Spivakovskiy Y; Kriulin I; Alshevskaya A; Moskalev A
    Pediatr Rheumatol Online J; 2021 Jan; 19(1):5. PubMed ID: 33407590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials.
    Ruperto N; Brunner HI; Quartier P; Constantin T; Wulffraat NM; Horneff G; Kasapcopur O; Schneider R; Anton J; Barash J; Berner R; Corona F; Cuttica R; Fouillet-Desjonqueres M; Fischbach M; Foster HE; Foell D; Radominski SC; Ramanan AV; Trauzeddel R; Unsal E; Levy J; Vritzali E; Martini A; Lovell DJ;
    Ann Rheum Dis; 2018 Dec; 77(12):1710-1719. PubMed ID: 30269054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease?
    Kilic O; Kasapcopur O; Camcioglu Y; Cokugras H; Arisoy N; Akcakaya N
    Rheumatol Int; 2012 Sep; 32(9):2675-9. PubMed ID: 21789614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis.
    Lovell DJ; Dare JA; Francis-Sedlak M; Ball J; LaMoreaux BD; Von Scheven E; Reinhardt A; Jerath R; Alpan O; Gupta R; Goldsmith D; Zeft A; Naddaf H; Gottlieb B; Jung L; Holt RJ
    Pediatr Rheumatol Online J; 2018 Jun; 16(1):41. PubMed ID: 29941047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
    Woolacott N; Bravo Vergel Y; Hawkins N; Kainth A; Khadjesari Z; Misso K; Light K; Asseburg C; Palmer S; Claxton K; Bruce I; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis.
    Murdaca G; Negrini S; Magnani O; Penza E; Pellecchio M; Gulli R; Mandich P; Puppo F
    Mod Rheumatol; 2018 May; 28(3):417-431. PubMed ID: 28837372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Etanercept in the treatment of disease-modifying anti-rheumatic drug (DMARD)-refractory polyarticular course juvenile idiopathic arthritis: experience from Japanese clinical trials.
    Mori M; Takei S; Imagawa T; Imanaka H; Nerome Y; Kurosawa R; Kawano Y; Yokota S; Sugiyama N; Yuasa H; Fletcher T; Wajdula JS
    Mod Rheumatol; 2011 Dec; 21(6):572-8. PubMed ID: 21479889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept.
    Verazza S; Davì S; Consolaro A; Bovis F; Insalaco A; Magni-Manzoni S; Nicolai R; Marafon DP; De Benedetti F; Gerloni V; Pontikaki I; Rovelli F; Cimaz R; Marino A; Zulian F; Martini G; Pastore S; Sandrin C; Corona F; Torcoletti M; Conti G; Fede C; Barone P; Cattalini M; Cortis E; Breda L; Olivieri AN; Civino A; Podda R; Rigante D; La Torre F; D'Angelo G; Jorini M; Gallizzi R; Maggio MC; Consolini R; De Fanti A; Muratore V; Alpigiani MG; Ruperto N; Martini A; Ravelli A;
    Pediatr Rheumatol Online J; 2016 Dec; 14(1):68. PubMed ID: 27993144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.
    Prince FH; Twilt M; ten Cate R; van Rossum MA; Armbrust W; Hoppenreijs EP; van Santen-Hoeufft M; Koopman-Keemink Y; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2009 May; 68(5):635-41. PubMed ID: 18413443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.